# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-26-003992
**Filing Date:** 2026-4
**Character Count:** 5656
**Document Hash:** 1c82be8d4d056e34059b0d18154d9086
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-003992.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001654954-26-003992

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260428

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 26904629

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of April 2026

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **79 New Oxford Street, London, WC1A 1DG**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

 **GSK plc (the 'Company**')

 **Vesting of 2023 Performance Share Plan Award**

This notification sets out the vesting details of a conditional share award made under the GSK 2017 Performance Share Plan ('PSP') to the Chief Financial Officer (CFO) on 27 April 2023 upon her joining GSK as CFO Designate.

Following the third anniversary of the grant, this 2023 PSP award has now vested on the same basis as the 2023 PSP awards which vested on 13 February 2026, with 82% vesting and 18% lapsed. Details of the performance measure outcomes and vesting levels are set out in the announcement of <u>17 February 2026</u>.

For the CFO, the vested shares are subject to an additional two-year holding period.

The notification that follows details the number of shares that vested under this 2023 PSP award for the CFO, including dividends accrued, on 27 April 2026. The balance of the award has lapsed.

The closing price of Ordinary Shares of GSK plc on the vesting date was £20.16.

Transaction notification

---

| | | | |
|:---|:---|:---|:---|
| **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| a) | Name<br>| Julie Brown | Julie Brown |
| b) | Position/status | Chief Financial Officer | Chief Financial Officer |
| c) | Initial notification/amendment<br>| Initial notification | Initial notification |
| **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| a) | Name | GSK plc | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| a) | Description of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction<br>| The vesting of awards granted in 2023 under the Company's 2017 Performance Share Plan | The vesting of awards granted in 2023 under the Company's 2017 Performance Share Plan |
| c) | Price(s) and volume(s) | Price(s) | Volume(s)<br>|
| c) | Price(s) and volume(s) | £0.00 | 243880<br>|
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| d) | Aggregated volume Price<br>|  |  |
| e) | Date of the transaction | 2026-04-27 | 2026-04-27 |
| f) | Place of the transaction<br>| N/A | N/A |

---

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: April 28, 2026 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---